ELEV — Elevation Oncology Cashflow Statement
0.000.00%
- $20.31m
- -$41.74m
Annual cashflow statement for Elevation Oncology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -17.3 | -32 | -95.1 | -45.7 | -44.5 |
Depreciation | |||||
Non-Cash Items | 0.052 | 1.57 | 3.28 | 3.17 | 4.26 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 4.9 | 0.283 | 6.29 | -13.7 | 3.84 |
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Cash from Operating Activities | -12.3 | -30.2 | -85.5 | -56.2 | -36.4 |
Capital Expenditures | -0.071 | 0 | -0.086 | 0 | — |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | — | -44.3 | 11.5 | -8.37 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -0.071 | 0 | -44.4 | 11.5 | -8.37 |
Financing Cash Flow Items | -0.174 | -0.011 | -0.47 | 0 | -0.17 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 90 | 97.1 | 29.5 | 48 | 44.9 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 77.7 | 66.9 | -100 | 3.34 | 0.209 |